Current Clinical Trials

Included on this page is clinical trial information and other test information supplied to the United Mitochondrial Disease Foundation. You may click on the link to learn more details about the trial, its purpose, who may participate, locations, and phone numbers for more information. THIS INFORMATION SHOULD BE USED IN CONJUNCTION WITH ADVICE FROM HEALTH CARE PROFESSIONALS. Most current studies are listed first.

Mitochondrial Disease Participants Needed for New Research Study at CHOP and HUP

Individuals with mitochondrial disease are needed for an observational research study at CHOP and HUP.  The study involves non-invasive MRI methods and blood glucose tests to focus on the relationship between mitochondrial disease, obesity, and risk of diabetes.  To be potentially eligible for the research study, we require the following:

-Medical history consistent with the clinical diagnosis of mitochondrial disease and a molecular genetic diagnosis
-Be between the ages of 18 to 65 years, inclusive
-Able to fast for 10 hours overnight
-Able to complete a 90-minute MRI scan and blood glucose testing

Participants will meet with the principal investigator, Dr. Shana McCormack, MD, and complete a 2-day study visit at HUP and CHOP, including an overnight stay.  We conduct only minimally-invasive procedures with full safety monitoring and there are no study medications or sedation.We may be able to provide reimbursement for travel, lodging, and food.  In addition, participants have the potential to obtain clinically-relevant laboratory results and compensation of up to $275.00.Additional information about the study is also located at https://clinicaltrials.gov/ct2/show/NCT02920671.  To learn more about the research study and determine your eligibility, contact Sara Nguyen at nguyens2@email.chop.edu or (267) 426-7165

 

REATA STUDY

There is an active clinical trial recruiting patients with mitochondrial myopathy. The trial is a double blind, placebo-controlled, multi-center  Phase 2 study of the safety and efficacy of omaveloxolone (RTA 408) in mitochondrial myopathies. To participate, you must be between the ages of 18 and 75, exercise intolerant, have a genetically confirmed mitochondrial disease (testing may be provided) and are willing to discontinue some medications. You must not be pregnant, planning a pregnancy, or breastfeeding. In this trial, a group of external clinical experts (physicians, researchers, and patient advocates) referred to as a DSMB (data safety monitoring board) reviews all unblinded data on a monthly basis to check on the progress of the study and make recommendations to the Sponsor to protect patient safety. Learn more about this clinical trial here. Or, download this important informational brochure here.

 

POSTED 12/15/16
MMPOWER UPDATE
Stealth BioTherapeutics
On December 6, 2016, Reenie McCarthy participated in an online presentation to the mitochondrial disease community to provide an update on Stealth BioTherapeutics’ clinical development program for primary mitochondrial myopathy. Following is a summary of the information presented during this event. finalmitoaction-webinar-summary12-15-16


LHON Study

A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide (MTP-131) Topical Ophthalmic Solution for the Treatment of LHON.
For information on this study, click here
Sponsor: Stealth BioTherapeutics


Posted 12/4/15
Safety Study of an Adeno-associated Virus Vector for Gene Therapy of Leber’s Hereditary Optic Neuropathy (LHON)
National Eye Institute- Dr. John Guy
For participation information, click here.
For additional background on this study, click here.

 


Posted 9/4/15
Mitochondrial Disease Research m.3243A>G Mutation Carriers and Maternal Relatives

Mitochondrial Disease

·   Mitochondria are small cellular organelles that are responsible for making energy.

·   Mitochondria contain DNA that instructs our cells to make some of the “machinery” needed for energy production.

·   Genetic mutations in the mitochondrial DNA (mtDNA) can result in serious health problems.

·   A common genetic mutation is the m.3243A>G which can result in a serious disorder calledMitochondrial Encephalopathy Lactic Acidosis and Stroke-like Episodes (MELAS).

·   Many of the m.3243A>G carriers do not have MELAS but may have clinical symptoms caused by the mutation such as hearing loss, gastrointestional issues and diabetes.

Purpose of the study: To improve our understanding of the implications of the m.3243A>G mutation through MRI/MRS, cognitive studies, blood and urine biomarkers, heteroplasmy levels and motor skills testing. This information could be used to identify future treatment options.

Where does this study take place?  You will travel to New York City, NY to attend a 1 day outpatient research visit.   Patients unwilling to travel may participate by providing blood and urine samples only at their local Quest Laboratory.

Who Qualifies?  Known carriers of the m.3243A>G mutation and their maternal relatives (carrier status is not required) and controls (non-carriers). 

BenefitsThis study may not benefit you directly, but may advance knowledge about mitochondrial disease caused by the m.3243A>G mutation.  The results of this study may help develop treatment options.

Privacy: Your study related samples and data will be given a unique identifying code that does not include any personally identifying information about you.

 Cost : Travel and hotel costs are covered by the study. Research procedures are free.

To participate, contact Kris Engelstad MS, CGC.  1-212-305-6834 or email ke4@cumc.columbia.edu.


Posted 8/18/15
George Washington University School of Health Sciences and Children’s Nation study on MELAS.
You may get details on this study by clicking here.

 


Posted 4/22/15
Reata Pharmaceuticals, Inc.
Recruiting Patients With Mitochondrial Myopathy

RTA 408 is a potent activator of Nrf2 and inhibitor of NF κB (nuclear factor kappa-light-chain-enhancer of activated B cells), and thus induces an antioxidant and anti-inflammatory phenotype. Several lines of evidence suggest that Nrf2 activation can increase mitochondrial respiration and biogenesis. Collectively, available data suggest that the ability of RTA 408 to activate Nrf2 and induce its target genes could potentially improve muscle function, oxidative phosphorylation, antioxidant capacity, and mitochondrial biogenesis in patients with mitochondrial myopathy.

 


Posted 3/25/15
UNIVERSITY HOSPITALS CASE MEDICAL CENTER 
Recruiting children and adults with PDC
Physicians at University Hospitals Case Medical Center in Cleveland, Ohio are currently recruiting children and adults with pyruvate dehydrogenase complex (PDC) deficiency and other disorders of pyruvate metabolism for a research study seeking to better understand the genetic causes, symptoms, usefulness of current treatments, and outcomes for these disorders. The research project involves completing a questionnaire about the individual or family’s medical history and experiences with PDC deficiency or other disorder of pyruvate metabolism, review of medical records by the researchers, and in some cases, genetic testing. No experimental treatments will be given as part of the study, and travel is not necessary. If you are interested in learning more about this research study, please contact Audrey Lynn, study coordinator, at 216-844-3936 option 2.

 


POSTED 2/13/15
Stealth BioTherapeutics Clinical Trial for patients with Mitochondrial Myopathy

 




POSTED 2/6/15
FRANCISCAN HOSPITAL FOR CHILDREN AND THE KENNEDY DAY SCHOOL
Participate in this important survey for parents of children with complex medical needs.

 



POSTED 01/05/15

CHILDRENS HOSPITAL OF PHILADELPHIA/UNIVERSITY OF PENNSYLVANIA

Mitochondrial Disease Study at the Children’s Hospital of Philadelphia and the University of Pennsylvania.

 


 

POSTED 01/05/15

LHON Research Project Mood Study

 




POSTED 11/14

OREGON HEALTH & SCIENCE UNIVERSITY

Center for Embryonic Cell and Gene Therapy

 


 

POSTED 11/03/14
REATA PHARMACEUTICALS, INC.

This two part study will evaluate the efficacy, safety, and pharmacodynamics of RTA 408 in the treatment of patients with mitochondrial myopathy.
For information about this study and eligibility, click here.

 


 

POSTED ON 6/14/14
VMP GENETICS
Mitochondrial myopathy patients needed for a new study evaluating the efficacy of a new, non-invasive screening and diagnostic tool.

Dr. Fran Kendall and VMP Genetics in Atlanta and the University of Georgia are looking to recruit patient subjects for a research study to investigate a new diagnostic and monitoring tool for mitochondrial diseases. The study design will include non-invasive investigative tools. (In other words, nothing will require sedation or considerable discomfort.) Due to our study hypothesis, we are looking to specifically recruit patients with clear mitochondrial myopathies to include those with CPEO/ptosis with mtDNA deletions, patients with documented molecular or OXPHOS biochemical abnormalities with ragged red fibers, or chronically increased CPK levels and/or episodes of rhabdomyolysis. The study design allows the testing to be completed in Dr. Kendall’s office or at the testing lab at UGA. There is a small travel stipend that could assist with your travel expenses. Although University and IRB research policy dictates that no additional information can be provided at this juncture to prevent bias in ascertaining subjects for the study, please contact Dr. Kendall through VMP Genetics at info@vmpgenetics.com  if you are interested in participating and additional information and details will be provided to you by the study coordinator, Hannah Bossie, at UGA.

 


 


POSTED ON 2/12/14

Cleveland Clinic and NAMDC
Natural History Study for Pearson Syndrome

Cleveland Clinic and the North American Mitochondrial Disease Consortium are recruiting patients with current or prior Pearson syndrome for a Natural History Study. The purpose of the study is to see how the condition progresses as the patient gets older.  We hope to better understand the natural evolution of the disease, why it is more severe in some patients and find potential areas to intervene with treatment. Patients will require annual or biannual visits to Cleveland Clinic for a medical evaluation along with a single blood draw. The study plans to follow patients for at least 3 years.

Dr. Sumit Parikh is the principal investigator in collaboration with Dr. Michio Hirano at Columbia and Dr. Suneet Agarwal at Boston Children’s. If interested in participating, please contact Dr. Parikh at 216-444-1994.

 


 


POSTED 2014
Baylor College of Medicine and Texas Children’s Hospital

Baylor College of Medicine and Texas Children’s Hospital are recruiting patients withMELAS (mitochondrial myopathy, encephalomyopathy, lactic acidosis, and stroke-like episodes) syndrome for a clinical study. The purpose of this study study is to see how the body handles sugar by measuring the amount of sugar that the body produces and breaks down (glucose metabolism). The results from people who have MELAS syndrome will be compared to those from people who do not have MELAS syndrome. By doing this comparison we may find that people with MELAS syndrome handle sugar differently, which would explain why many develop diabetes.  Adults affected with MELAS syndrome and carrying the 3243 A>G mutation can participate. Subject with MELAS will be admitted once to the General Clinical Research Center (GCRC) at Texas Children’s Hospital for 2 days (1 overnight). Glucose metabolism will be measured by a safe stable isotope infusion technique that involves placing small tubes in veins (IV catheter), blood sampling, and injecting a harmless stable isotope. The principal investigator is Dr. William Craigen. Subjects interested in participation or getting more information can contact Dr. Lisa Emrick at email: emrick@bcm.edu, phone: 832-822-4289

 


 

POSTED 2014
Oregon Health & Science University

Oregon Health & Science University is recruiting women to donate eggs to a research study. The study is evaluating new techniques for correcting mitochondrial gene mutations in eggs. To qualify, you must be: